Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Equity (2016 - 2025)

Cytosorbents (CTSO) has disclosed Return on Equity for 13 consecutive years, with 1.15% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 129.0% year-over-year to 1.15%, compared with a TTM value of 1.15% through Sep 2025, down 129.0%, and an annual FY2024 reading of 0.95%, down 70.0% over the prior year.
  • Return on Equity was 1.15% for Q3 2025 at Cytosorbents, down from 0.85% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.13% in Q3 2024 and bottomed at 1.3% in Q4 2024.
  • Average Return on Equity over 5 years is 0.62%, with a median of 0.69% recorded in 2022.
  • The sharpest move saw Return on Equity skyrocketed 133bps in 2021, then plummeted -129bps in 2025.
  • Year by year, Return on Equity stood at 0.37% in 2021, then plummeted by -139bps to 0.88% in 2022, then soared by 61bps to 0.35% in 2023, then plummeted by -275bps to 1.3% in 2024, then rose by 11bps to 1.15% in 2025.
  • Business Quant data shows Return on Equity for CTSO at 1.15% in Q3 2025, 0.85% in Q2 2025, and 0.86% in Q1 2025.